Enavogliflozin clinical trials
Also written DWP16001.
How each study uses Enavogliflozin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Enavogliflozin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
33 studies that test it; most in 2023 (6)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 8
Daewoong Pharmaceutical Co. LTD. (25) · Yonsei University (3) · Asan Medical Center (1) · Duk-Woo Park, MD (1) · Seoul St. Mary's Hospital (1) · Seoul National University Bundang Hospital (1) · Korea University Anam Hospital (1)
Often tested with
Tested in the same studies.
DWC202511 (1) · DWC202512 (1) · DWJ1525 (1) · DWC202101 (1) · DWC202518 (1) · DWC202407 (1) · DWC202408 (1) · DWC202213 (1)
Related medicines
As reviewed, each with the page that says it.
- One of SGLT2 inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 2 in phase 3
Studies that test Enavogliflozin, phase 3 first.
- Jun 2027Enavogliflozin Outcome Trial in Functional Tricuspid RegurgitationPhase 3 · Asan Medical Center
- Nov 2027To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes MellitusPhase 3 · Daewoong Pharmaceutical Co. LTD.
- Nov 2026ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathyPhase 4 · Yonsei University
- Dec 2026Enavogliflozin vs. Pioglitazone on Glucose and AtherosclerosisPhase 4 · Seoul National University Bundang Hospital
- Apr 2027Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThyPhase 4 · Seoul St. Mary's Hospital
- May 2027Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter AblationPhase 4 · Yonsei University
Studies
Open first, then newest update. How each study uses Enavogliflozin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 33
- ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve ReplacementRecruitingPhase 4Duk-Woo Park, MDNCT05672836Written as Enavogliflozin
- Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThyRecruitingPhase 4Seoul St. Mary's HospitalNCT07240844Written as Enavogliflozin 0.3mg
- To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes MellitusNot yet recruitingPhase 3Daewoong Pharmaceutical Co. LTD.NCT07619833Written as DWP16001
- Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter AblationRecruitingPhase 4Yonsei UniversityNCT06528262Written as Enavogliflozin
- Enavogliflozin vs. Pioglitazone on Glucose and AtherosclerosisRecruitingPhase 4Seoul National University Bundang HospitalNCT06399835Written as Enavogliflozin
- Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in ObesityRecruitingPhase 4Korea University Anam HospitalNCT06782139Written as Enavogliflozin
- ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathyRecruitingPhase 4Yonsei UniversityNCT06580717Written as enavogliflozin 0.3mg
- Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy AdultsNot yet recruitingPhase 1Daewoong Pharmaceutical Co. LTD.NCT06644404Written as DWP16001 0.3mg
- A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus PatientsRecruitingPhase 4Yonsei UniversityNCT06642623Written as Enavogliflozin
- Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment PatientsNot yet recruitingPhase 3Daewoong Pharmaceutical Co. LTD.NCT06606093Written as DWP16001 0.3mg
- A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes MellitusRecruitingPhase 3Daewoong Pharmaceutical Co. LTD.NCT05466643Written as DWP16001 0.3mg
- To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic FunctionRecruitingPhase 1Daewoong Pharmaceutical Co. LTD.NCT05747664Written as DWP16001
- Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes MellitusNot yet recruitingPhase 3Daewoong Pharmaceutical Co. LTD.NCT06141980Written as DWP16001 0.3 mg
- To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult VolunteersRecruitingPhase 1Daewoong Pharmaceutical Co. LTD.NCT05797922Written as DWP16001
- Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy AdultsCompletedPhase 1Daewoong Pharmaceutical Co. LTD.NCT07213310Written as DWP16001
- Enavogliflozin Outcome Trial in Functional Tricuspid RegurgitationActive, not recruitingPhase 3Asan Medical CenterNCT06027307Written as Enavogliflozin
- The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on MetforminActive, not recruitingPhase 3Daewoong Pharmaceutical Co. LTD.NCT05505994Written as DWP16001
- To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose CombinationStatus unknownPhase 1Daewoong Pharmaceutical Co. LTD.NCT05737771Written as DWP16001
- Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics of DWP16001 Drug A and CCompletedPhase 1Daewoong Pharmaceutical Co. LTD.NCT05465668Written as DWP16001 Drug A
- The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.CompletedPhase 3Daewoong Pharmaceutical Co. LTD.NCT04632862Written as DWP16001
Codes
What other systems call Enavogliflozin · ClinicalTrials.gg INT002065
- MeSH (NLM) C000729921EnavogliflozinOne source ClinicalTrials.gov
- UNII (FDA) Z5MR2Y1IJJENAVOGLIFLOZINConfirmed FDA, Wikidata
- Wikidata Q123598885enavogliflozinConfirmed FDA, Wikidata
- NCI Thesaurus C171901EnavogliflozinOne source FDA
- DrugBank DB18970One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729921 | Enavogliflozin | One source ClinicalTrials.gov |
| UNII (FDA) | Z5MR2Y1IJJ | ENAVOGLIFLOZIN | Confirmed FDA, Wikidata |
| Wikidata | Q123598885 | enavogliflozin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C171901 | Enavogliflozin | One source FDA |
| DrugBank | DB18970 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.